MAX-ing out MYC: A novel small molecule inhibitor against MYC-dependent tumors

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Chio, Iok In Christine ^a   Yordanov, Georgi ^a   Tuveson, David A ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; SMALL MOLECULE TRANSPORT AGENT; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; ANTINEOPLASTIC AGENT; KRAS2 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; PROTEIN P21; THIAZOLE DERIVATIVE;

DOWNSTREAM PROCESSING; EDITORIAL; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; NONHUMAN; ONCOGENE K RAS; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; GENETICS; MALE; PANCREATIC NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; MALE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); THIAZOLES;

EID: 84922391687     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju365     Document Type: Editorial

References (22)

1. Gabay M, Li Y, Felsher DW. MYC Activation Is a Hallmark of Cancer Initiation and Maintenance. Cold Spring Harb Perspect Med. 2014;4(6):a014241-a014241.
2. Dang CV. MYC on the Path to Cancer. Cell. 2012;149(1):22-35.
3. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011;25(9):907-916.
4. Soucek L, Whitfield JR, Sodir NM, et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013;27(5):504-513.
5. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
6. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
7. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012;109(47):19408-19413.
8. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72(2):233-245.
9. Guo J, Parise R, Joseph E, et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5- [4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009;63(4):615-625.
10. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014;74(11):2913-2921.
11. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer. 2011;11(11):775-791.
12. Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012;109(14):5299-5304.
13. Sun Q, Burke JP, Phan J, et al. Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation. Angew Chem Int Ed Engl. 2012;51(25):6140-6143.
14. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548-551.
15. Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013;497(7451):638-642.
16. Zhong H, Sanchez C, Spitrzer D, et al. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS ONE. 2013;8(10):e77243.
17. Sears R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14(19):2501-2514.
18. Saborowski M, Saborowski A, Morris JP, et al. A modular and flexible ESCbased mouse model of pancreatic cancer. Genes Dev. 2014;28(1):85-97.
19. Stellas D, Szabolcs M, Koul S, et al. Therapeutic effects of anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014;106(12):dju320 doi:10.1093/jnci/dju320.
20. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483.
21. Bardeesy N, Cheng K-H, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130-3146.
22. Ying H, Elpek KG, Vinjamoori A, et al. PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB-Cytokine Network. Cancer Discovery. 2011;1(2):158-169.